In a HER-2/neu tumor model, treatment with gemcitabine, HER-2/neu vaccine and anti-glucocorticoid tumor necrosis factor receptor related protein (GITR) mAbs showed potent therapeutic anti-tumor immunity, in addition to protection against pre-existing tumors (Ko et al., 2007). Here, TNFRSF18 is linked to neoplasm.